| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.009 | 0.8 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.046 | 0.8 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.0099 | 0.8 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.012 | 0.8 |